Huntington’s disease (HD) is a progressive neurological condition. Two factors that impede clinical trials in the HD space are the slow progression of the disease that makes it difficult to detect treatment-specific changes over a relatively short period of time and the number of people wanting to know if they are carriers of the mutation.
To read more, click here.